Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:06:20 EDT Mon 14 Jul 2025
Enter Symbol
or Name
USA
CA



Z:RCUS - ARCUS BIOSCIENCES INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RCUS - Z9.59.46·9.653.99.65+0.303.2607.65,3814,1089.255  9.68  9.1718.98  6.5116:07:26Jul 1015 min RT 2¢

Recent Trades - Last 10 of 4108
Time ETExPriceChangeVolume
16:07:26Z9.650.3219,537
16:05:16Z9.650.322
16:04:09Z9.650.321
16:04:07Z9.650.321
16:01:59Z9.650.32300
16:01:49Z9.650.32477
16:01:44Z9.650.322,176
16:01:32Z9.650.32353
16:01:20Z9.650.32371
16:01:10Z9.650.32189

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-10 08:30U:RCUSNews ReleaseArcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
2025-07-09 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-06-24 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-06-01 10:45U:RCUSNews ReleaseInitial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
2025-05-27 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-05-09 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-05-06 16:05U:RCUSNews ReleaseArcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
2025-04-24 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-04-23 16:05U:RCUSNews ReleaseArcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
2025-04-22 16:05U:RCUSNews ReleaseArcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
2025-04-09 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-03-25 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-02-26 16:35U:RCUSNews ReleaseArcus Biosciences to Participate in Two Upcoming Investor Conferences
2025-02-25 16:05U:RCUSNews ReleaseArcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
2025-02-24 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-02-18 06:57U:RCUSNews ReleaseArcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
2025-02-18 06:52U:RCUSNews ReleaseArcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
2025-02-15 15:45U:RCUSNews ReleaseNew Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
2025-02-11 16:35U:RCUSNews ReleaseArcus Biosciences Announces New Employment Inducement Grants
2025-02-10 17:00U:RCUSNews ReleaseArcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium